NCT02849782View on ClinicalTrials.gov

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 4, 2014

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Fampridine

Oral intake of 10 mg twice daily

Trial Locations (1)

25030

CHU Jean Minjoz, Besançon

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02849782 - Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. | Biotech Hunter | Biotech Hunter